Alumis ALMS
NASDAQ ALMS
$9.90 +0.10 (+1.02%)
At close: Sep 10, 2026 · 4:00 PM EDT

Alumis (ALMS) Research & Development (2023 - 2026)

Alumis' (ALMS) quarterly Research & Development came in at $85.3 million in Q2 2026, down 21.53% year-over-year from $108.8 million in Q2 2025, and up 3.08% quarter-over-quarter from $82.8 million in Q4 2025.

Analysis

Alumis (ALMS) Research & Development (2023 - 2026) Analysis & Trends

Alumis (ALMS) has reported Research & Development for 4 consecutive years, with $85.3 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Research & Development fell 21.53% year-over-year to $85.3 million in Q2 2026; TTM through Jun 2026 was $374.7 million, a 1.5% decrease from a year earlier, with the FY2025 full-year figure at $386.0 million, up 45.36% from the prior year.
  • Research & Development was $85.3 million for Q2 2026 at Alumis, up from $82.8 million in the prior quarter.
  • Over five years, Research & Development peaked at $108.8 million in Q2 2025 and troughed at $32.8 million in Q2 2023.
  • A 4-year average of $70.2 million and a median of $84.1 million in 2025 frame the typical range for Research & Development.
  • Across the five-year window, Research & Development jumped 152.0% in 2024 and retreated 21.53% in 2026, its largest moves.
  • Over 4 years, Research & Development stood at $34.6 million in 2023, then surged by 152.0% to $87.2 million in 2024, then retreated by 5.07% to $82.8 million in 2025, then increased by 3.08% to $85.3 million in 2026.
  • The last three Research & Development figures came in at $85.3 million (Q2 2026), $82.8 million (Q4 2025), and $97.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 1.87 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 1.76 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 993.80 Mn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.63 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -486.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 651.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 413.13 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 529.60 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 202.02 Mn
10 Alumis 1.27 Bn 765.76 Mn - 85.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 85.34 Mn
Dec 31, 2025 82.79 Mn
Sep 30, 2025 97.84 Mn
Jun 30, 2025 108.76 Mn
Mar 31, 2025 96.62 Mn
Dec 31, 2024 87.20 Mn
Sep 30, 2024 87.82 Mn
Jun 30, 2024 48.57 Mn
Mar 31, 2024 41.96 Mn
Dec 31, 2023 34.61 Mn
Sep 30, 2023 37.79 Mn
Jun 30, 2023 32.85 Mn